VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients.
Eur J Clin Pharmacol
; 64(9): 889-94, 2008 Sep.
Article
em En
| MEDLINE
| ID: mdl-18542936
ABSTRACT
OBJECTIVES:
The objective of this study was to determine the quantitative influence of vitamin K epoxide reductase complex subunit 1 (VKORC1) and cytochrome P450 2C9 (CYP 2C9) polymorphisms on warfarin dose requirements in Turkish patients.METHODS:
A total of 205 patients taking warfarin for >2 months were enrolled in the study. Deoxyribonucleic acid (DNA) samples from these patients were genotyped for polymorphisms in VKORC1 and CYP2C9 genes. A linear regression analysis was used to determine the independent effects of genetic and non-genetic factors on mean warfarin dose requirements.RESULTS:
The VKORC1 promoter polymorphism (3673 G>A) was associated with differences in weekly mean varfarin dose for GG genotype the dose was 43.18 mg/week, for GA genotype 33.78 mg/week and for AA genoype 25.83 mg/week (P < 0.0001). Patients who carried VKORC1 and CYP2C9 variants needed a 40% lower mean weekly warfarin dose compared to wild types. Variables associated with lower warfarin dose requirements were VKORC1 3673 AA or GA genotype (both P < 0.0001), one or two CYP2C9 variant alleles (both P < 0.0001), increasing age (P < 0.0001) and non-indication of venous thromboembolism for warfarin therapy (P = 0.002).CONCLUSION:
Polymorphisms in VKORC1 and CYP2C9 genes were important determinants of warfarin dose requirements in Turkish patients.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Polimorfismo Genético
/
Varfarina
/
Hidrocarboneto de Aril Hidroxilases
/
Oxigenases de Função Mista
/
Anticoagulantes
Tipo de estudo:
Risk_factors_studies
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
País/Região como assunto:
Asia
Idioma:
En
Revista:
Eur J Clin Pharmacol
Ano de publicação:
2008
Tipo de documento:
Article
País de afiliação:
Turquia